OXFORD BIODYNAMICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.751 GBX | +0.14% |
|
-1.64% | -72.32% |
| May. 16 | Bens Creek considers administration; Nexxen inks deal | AN |
| May. 16 | Oxford BioDynamics, plc and King's College London Collaborate on RA | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 154K 195K | Sales 2023 | 510K 646K | Capitalization | 74.85M 94.82M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -7.6M | Net income 2023 | -10M -12.67M | EV / Sales 2022 | 108 x |
| Net Debt 2022 | 5.14M 6.51M | Net Debt 2023 | 1.19M 1.51M | EV / Sales 2023 | 149 x |
| P/E ratio 2022 |
-1.71
x | P/E ratio 2023 |
-5.04
x | Employees | 45 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.55% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.14% | ||
| 1 week | -1.64% | ||
| Current month | -9.24% | ||
| 1 month | -12.91% | ||
| 3 months | -42.16% | ||
| 6 months | -77.85% | ||
| Current year | -72.32% |
1 week
7.50
8.50
1 month
7.509.80
Current year
7.5036.90
1 year
7.5052.00
3 years
7.5073.88
5 years
7.50170.00
10 years
7.50278.82
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 62 | 07-04-22 | |
Jon Burrows
CEO | Chief Executive Officer | - | 20-03-22 |
Paul Stockdale
DFI | Director of Finance/CFO | - | 17-09-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Diggle
BRD | Director/Board Member | 60 | 16-10-03 |
David Holbrook
BRD | Director/Board Member | 63 | 19-04-04 |
Jon Burrows
CEO | Chief Executive Officer | - | 20-03-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 7.751 | +0.14% | 244 026 |
| 24-05-16 | 7.74 | -1.28% | 963,459 |
| 24-05-15 | 7.84 | -0.76% | 262,866 |
| 24-05-14 | 7.9 | +0.13% | 485,452 |
| 24-05-13 | 7.89 | +0.13% | 54,186 |
Delayed Quote London S.E., May 17, 2024 at 08:35 am EDT
More quotes
Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patientâs therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
Calendar
2024-05-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -72.32% | 19.84M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +49.39% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- OBD Stock
